Business
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
SAN DIEGO, May 07, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update.
About this update from Janux Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":254,"url":"https://media.zenfs.com/en/business-wire.com/06703cf313459043ba501700374e5736"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C28OBclcrtp3caP.CSHByw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwOA--/https://media.zenfs.com/en/business-wire.com/06703cf313459043ba501700374e5736","width":480,"height":254},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/fVUrymgBAAOEHzrvq7ivvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMzOQ--/https://media.zenfs.com/en/business-wire.com/06703cf313459043ba501700374e5736","width":480,"height":254}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"JANX007 continues to enroll in its Phase 1b taxane-naïve patient population, including combination cohorts with darolutamide","length":124,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Initiated clinical evaluation of JANX014, a double-masked PSMA-TRACTr candidate","length":79,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"JANX011 Phase 1 study ongoing in healthy volunteers","length":51,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Discontinued development of JANX008 following completion of Phase 1a","length":68,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Achieved development candidate nomination under Bristol Myers Squibb collaboration, triggering milestone payment","length":112,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong cash position supporting continued pipeline execution","length":60,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"text","content":"SAN DIEGO, May 07, 2026--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended March 31, 2026, and provided a business update.","length":290,"tagName":"p"},{"type":"text","content":""Our commitment to advancing a prostate cancer franchise is demonstrated by our continued progress with JANX007, clinical initiation of JANX014, and advancement of JANX013 toward the clinic," said David Campbell, Ph.D., President and CEO ...